A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System
Liver metastases are a major management problem; since they occur in tumors of different origin, they are often multiple, difficult to visualize and can lie dormant for many years. Patients with liver metastases usually die of their disease, mostly due to liver failure, since systemic treatments are...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/1/70 |
| _version_ | 1797542348951912448 |
|---|---|
| author | Pier Francesco Ferrucci Emilia Cocorocchio Guido Bonomo Gianluca Maria Varano Paolo Della Vigna Franco Orsi |
| author_facet | Pier Francesco Ferrucci Emilia Cocorocchio Guido Bonomo Gianluca Maria Varano Paolo Della Vigna Franco Orsi |
| author_sort | Pier Francesco Ferrucci |
| collection | DOAJ |
| description | Liver metastases are a major management problem; since they occur in tumors of different origin, they are often multiple, difficult to visualize and can lie dormant for many years. Patients with liver metastases usually die of their disease, mostly due to liver failure, since systemic treatments are unable to eradicate micro-metastasis, and interventional loco-regional procedures cannot treat all existing ones. Cholangiocarcinoma (CCA) is the second most common primary liver tumor, showing a poor overall prognosis. When resection is not possible, treatment options include tumor-focused or local ablative therapy, organ-focused or regional therapy and systemic therapy. We reviewed available loco-regional therapeutic options, with particular focus on the CHEMOSAT<sup>®</sup> Melphalan/Hepatic Delivery System (CS-HDS), which is uniquely positioned to perform a percutaneous hepatic perfusion (PHP), in order to treat the entire liver as a standalone or as complementary therapy. This system isolates the liver circulation, delivers a high concentration of chemotherapy (melphalan), filters most chemotherapy out of the blood and is a repeatable procedure. Most CS-HDS benefits are demonstrated in liver-predominant diseases, like liver metastasis from uveal melanoma (UM), hepatocarcinoma (HCC) and CCA. More than 650 procedures have been performed in Europe to date, mostly to treat liver metastases from UM. In CCA, experience is still limited, but retrospective analyses have been reported, while phase II and III studies are closed, waiting for results or ongoing. |
| first_indexed | 2024-03-10T13:29:21Z |
| format | Article |
| id | doaj.art-b8ae8d92952741088679d866bf836d15 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T13:29:21Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-b8ae8d92952741088679d866bf836d152023-11-21T08:17:57ZengMDPI AGCells2073-44092021-01-011017010.3390/cells10010070A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery SystemPier Francesco Ferrucci0Emilia Cocorocchio1Guido Bonomo2Gianluca Maria Varano3Paolo Della Vigna4Franco Orsi5Tumor Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, 20141 Milan, ItalyHematoncology Division, European Institute of Oncology, IRCCS, 20141 Milan, ItalyInterventional Radiology Division, European Institute of Oncology, IRCCS, 20141 Milan, ItalyInterventional Radiology Division, European Institute of Oncology, IRCCS, 20141 Milan, ItalyInterventional Radiology Division, European Institute of Oncology, IRCCS, 20141 Milan, ItalyInterventional Radiology Division, European Institute of Oncology, IRCCS, 20141 Milan, ItalyLiver metastases are a major management problem; since they occur in tumors of different origin, they are often multiple, difficult to visualize and can lie dormant for many years. Patients with liver metastases usually die of their disease, mostly due to liver failure, since systemic treatments are unable to eradicate micro-metastasis, and interventional loco-regional procedures cannot treat all existing ones. Cholangiocarcinoma (CCA) is the second most common primary liver tumor, showing a poor overall prognosis. When resection is not possible, treatment options include tumor-focused or local ablative therapy, organ-focused or regional therapy and systemic therapy. We reviewed available loco-regional therapeutic options, with particular focus on the CHEMOSAT<sup>®</sup> Melphalan/Hepatic Delivery System (CS-HDS), which is uniquely positioned to perform a percutaneous hepatic perfusion (PHP), in order to treat the entire liver as a standalone or as complementary therapy. This system isolates the liver circulation, delivers a high concentration of chemotherapy (melphalan), filters most chemotherapy out of the blood and is a repeatable procedure. Most CS-HDS benefits are demonstrated in liver-predominant diseases, like liver metastasis from uveal melanoma (UM), hepatocarcinoma (HCC) and CCA. More than 650 procedures have been performed in Europe to date, mostly to treat liver metastases from UM. In CCA, experience is still limited, but retrospective analyses have been reported, while phase II and III studies are closed, waiting for results or ongoing.https://www.mdpi.com/2073-4409/10/1/70intrahepatic cholangiocarcinomaliver metastasisregional therapypercutaneous hepatic perfusion |
| spellingShingle | Pier Francesco Ferrucci Emilia Cocorocchio Guido Bonomo Gianluca Maria Varano Paolo Della Vigna Franco Orsi A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System Cells intrahepatic cholangiocarcinoma liver metastasis regional therapy percutaneous hepatic perfusion |
| title | A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System |
| title_full | A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System |
| title_fullStr | A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System |
| title_full_unstemmed | A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System |
| title_short | A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System |
| title_sort | new option for the treatment of intrahepatic cholangiocarcinoma percutaneous hepatic perfusion with chemosat delivery system |
| topic | intrahepatic cholangiocarcinoma liver metastasis regional therapy percutaneous hepatic perfusion |
| url | https://www.mdpi.com/2073-4409/10/1/70 |
| work_keys_str_mv | AT pierfrancescoferrucci anewoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT emiliacocorocchio anewoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT guidobonomo anewoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT gianlucamariavarano anewoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT paolodellavigna anewoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT francoorsi anewoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT pierfrancescoferrucci newoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT emiliacocorocchio newoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT guidobonomo newoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT gianlucamariavarano newoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT paolodellavigna newoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem AT francoorsi newoptionforthetreatmentofintrahepaticcholangiocarcinomapercutaneoushepaticperfusionwithchemosatdeliverysystem |